menu
    • menu
    [{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Funding","leadProduct":"ALM-488","moa":"Extracellular matrix nerve","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alume Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Alume Biosciences

    Menu

    Alume Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

                            Details : Bevonescein is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of General Surgery.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 28, 2024

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Feasibility Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

                            Details : Bevonescein is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 29, 2024

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing H...

                            Details : ALM-488 is a proprietary fluorescent peptide-dye conjugate in the visible spectrum and can be visualized with fluorescently enabled instrumentation including filter modified loupe systems, portable handheld systems, microscopes and laparoscopes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

                            Details : Bevonescein is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of General Surgery.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 17, 2022

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alume Biosciences Granted FDA Fast Track Designation Of ALM-488 For Surgical Nerve Visualization

                            Details : ALM-488 is a fluorescently labelled nerve targeting drug, which acts as an adjunct for the visualization of nerves at risk for injury during head and neck surgery. The Fast Track designation is based on a Phase 1/2 trial in patients undergoing head and n...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 12, 2021

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 in Patients Undergoing He...

                            Details : Alume is conducting a Phase 1/2 clinical trial of ALM-488 in patients undergoing Head and Neck surgery. The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume's fluorescent nerve targeting agent in an ongoing Phase 1/2 c...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : ALM-488

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Alume Biosciences

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

                            Details : Bevonescein is a Peptide-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Parotid Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Peptide-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 09, 2020

                            Lead Product(s) : Bevonescein

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth